Cardio Diagnostics Holdings (NASDAQ: CDIO) is positioned at the intersection of artificial intelligence and precision medicine, using its proprietary AI-driven Multi-Omics Engine to analyze genetic and epigenetic biomarkers for early detection and diagnosis of coronary heart disease. The company's blood-based Epi+Gen CHD and PrecisionCHD tests aim to assess heart attack risk and identify coronary heart disease, including nonobstructive forms that conventional diagnostic methods may miss. This approach addresses a cardiovascular disease market that is projected to grow from $393 billion in annual healthcare costs in 2020 to $1.4 trillion by 2050, according to the press release.
The company has strengthened its commercialization efforts by securing finalized CMS reimbursement rates and dedicated CPT laboratory codes, expanding U.S. provider partnerships, and launching its first international expansion in India. With a proprietary, AI-driven platform that has achieved reimbursement milestones, growing provider adoption, and evidence supporting its ability to detect what traditional tools miss, Cardio Diagnostics occupies a position that is both scientifically grounded and commercially actionable in the diagnostics landscape. For more details, see the full article at https://nnw.fm/9LJ2r.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease. For more information, visit https://cdio.ai/. The latest news and updates relating to CDIO are available in the company’s newsroom at https://nnw.fm/CDIO.
